Your session is about to expire
← Back to Search
Pembrolizumab + Olaparib for Head and Neck Cancer
Study Summary
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have advanced stage mouth or throat cancer, not caused by HPV unless I have a heavy smoking history.I am fully active or can carry out light work.I cannot swallow pills before starting the study treatment.I have at least one cancer lesion that can be monitored through scans.I haven't had treatments aimed at curing my cancer and haven't been in a drug/device trial recently.I am taking steroids only for immune-related symptoms, not for other reasons.I have had cancer before, but it won't affect this study's treatment, except for head and neck cancer treated within the last 3 years.I do not have any severe, uncontrolled health issues.I am over 18 years old.I cannot receive cisplatin as per my treatment plan.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
- Group 1: Single Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
What is the size of the cohort involved in this investigation?
"Affirmative. According to the information maintained by clinicaltrials.gov, this medical trial is actively recruiting participants since it was initially posted on September 2nd 2022 and updated lastly on October 25th of that same year. 45 patients need to be sourced from two different hospital locations."
Has the FDA granted its seal of approval to Pembrolizumab?
"With some data to back up its safety, Pembrolizumab was given a score of 2 since this is only Phase 2 trial and there are no results confirming its efficacy."
Is it currently possible for individuals to join this experiment?
"The information published on clinicaltrials.gov reveals that this medical trial is presently seeking willing participants. This investigation was initially announced on September 2nd 2022, and the most recent update occured on October 25th of the same year."
Share this study with friends
Copy Link
Messenger